Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 5/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.36 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ADH5 | P11766 | 1/20 | 0.34 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4542467 | 0.84 | FASN (0.62) | FASNALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4539490 | 0.83 | FASN (0.70) | FASNGAAALDH1A1MEN1KMT2A | |
| SCHEMBL4541301 | 0.83 | FASN (0.68) | FASNGAAALDH1A1MEN1KMT2A | |
| SCHEMBL5019467 | 0.83 | FASN (0.63) | FASNALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4561699 | 0.81 | FASN (0.67) | FASNALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4541477 | 0.81 | FASN (0.66) | FASNGAAALDH1A1MEN1KMT2A | |
| SCHEMBL4561867 | 0.80 | FASN (0.64) | FASNALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4561314 | 0.80 | FASN (0.64) | FASNALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4536313 | 0.79 | FASN (0.63) | FASNALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4536476 | 0.79 | FASN (0.80) | FASNALDH1A1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020150423-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | YUMANITY THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| US-20200222400-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2020-07-16 | — | — | US | disclosed |
| US-20130237535-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-09-12 | — | — | US | disclosed |
| US-20130237535-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-09-12 | — | — | US | disclosed |
| WO-2012064642-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200222400-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, CLN6, OTC | FASN 2790/4885GAA 110/4885ALDH1A1 934/4885 |
| US-20130237535-A1 | FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | FASN 1/4885GAA 1747/4885ALDH1A1 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.